



WHO Product Development for Vaccines Advisory Committee Meeting (PD-VAC)

8-10 September 2014

Venue: Salle B, WHO HQ, Geneva, Switzerland

AGENDA

Day 1, Monday, 8 September 2014

- 09:00 - 09:15 Uli Fruth
Team Leader, Initiative for Vaccine Research
- 09:15 - 09:45 Setting the scene: Current landscape in vaccine R&D, and WHO's role. The role of other WHO committees including SAGE. Background to initiation of PDVAC and its role. What is in scope and what is out of scope.
Uli Fruth & Vasee Moorthy
- 09:45 - 09:50 Role of Expert Committee on Biological Standardisation: Guidelines and Recommendations for National Regulatory Authorities Ivana Knezevic
- 09:50 - 10:00 Future link between PDVAC and Global Vaccine Action Plan R&D indicators
Joachim Hombach
- 10:00 - 10:10 GAVI criteria and process for Vaccine Investment Strategy Judith Kallenberg
- 10:10 - 10:30 Discussion
- 10:30 - 11:00 *Coffee break***
- 11:00 – 12:00 **Tuberculosis** Georges Thiry
Vaccine development pipeline: progress and challenges (30 minutes)
Discussion (30 minutes)
- 12:00 - 13:00 *Lunch break***
- 13:00 - 14:30 **Respiratory Syncytial Virus (RSV)**
Eric Simoes *The disease, the pathogen and the unmet medical need (25 minutes)*
Ruth Karron *Vaccine development pipeline: progress and challenges (25 minutes)*
WHO's response to the RSV problem (10 minutes)
Discussion (30 minutes)
- 14:30 – 15:45 ***Streptococcus pneumoniae (focusing on protein and whole cell)***
Mark Alderson
Group B Streptococcus



Vaccine development pipeline: progress and challenges (30 minutes)
Discussion (30 minutes – pneumococcus, 15 minutes – Group B Streptococcus)

15:45 - 16:15 ***Coffee break***

16:00 - 17:30 **Enteric Pathogens**

16:00 – 16:45 **Second-generation Rotavirus vaccines** Duncan Steele

Vaccine development pipeline: progress and challenges (15 minutes)

Discussion (30 minutes)

16:45 – 17:30 **Other enteric pathogens including *E. coli*, Shigella, Non-typhi salmonella, Paratyphoid, Cryptosporoidosis** Duncan Steele

Vaccine development pipeline: progress and challenges (15 minutes)

Discussion (30 minutes)

Day 2, Tuesday, 9 September 2014

09:00 – 10:00 **Universal Influenza Vaccines** Barney Graham

Vaccine Pipeline (30 minutes)

Discussion (30 minutes)

10:00 - 11:00 **Malaria** Salim Abdulla

Vaccine development pipeline: progress and challenges (30 minutes)

Discussion (30 minutes)

11:00 - 11:30 ***Coffee break***

11:30 - 13:00 **HIV** Lynn Morris **& HSV** Christine Johnston

HIV Vaccine development pipeline: progress and challenges (30 minutes)

Discussion (30 minutes)

HSV vaccine development pipeline & Discussion, Christine Johnston (30 minutes)

13:00 - 14:00 ***Lunch break***

14:50 - 15:40 **Group A streptococcus** Florian Schodel

Vaccine development pipeline: progress and challenges (20 minutes)

Discussion (30 minutes)

15:40 - 16:00 ***Coffee break***

16:00 - 17:00 Clinical Trial Results Reporting for Vaccine RCT: A recent survey from the influenza, HPV, pneumococcal, rotavirus, meningococcal vaccine fields
Lamberto Manzoli (30 minutes)



Background to development of WHO position on Clinical Trial Results Reporting (10 minutes)

Vasee Moorthy

Open session discussion (up to 20 minutes)

17:00 – 17:30 Update on **Ebola** vaccine activities under the framework of the WHO emergency response
Vasee Moorthy

Day 3, Wednesday, 10 September 2014: Open Session to 1130 am: Closed session for Committee members only starts at 1130 am.

09:00 – 09:50 **Neglected Tropical Diseases: Schistosomiasis, Leishmaniasis, Hookworm and Chagas Disease** Peter Hotez
Vaccine development pipeline: progress and challenges (20 minutes)
Discussion (30 minutes)

09:50 - 10:30 **Cross-Cutting Issues: Facilitating vaccine R&D beyond pathogen-specific priorities for development.** Identifying cross-cutting areas that stimulate progress in vaccine development. Role for PD-VAC in highlighting priority non pathogen-specific issues.
Discuss role vs other WHO committees
Potential topics meriting discussion:
WHO normative guidance on challenge trials

10:30 – 11:00 Coffee Break

1100 – 11:30 Wrap up open session, including recap on likely next steps

1130 – 12:30 CLOSED session begins (see below)

12:30 - 14:00 Lunch

CLOSED SESSION

14:00 - 17:00 **Committee closed session** to review outcomes of discussion over days 1 & 2 and formulate recommendations for prioritization of WHO's work including a ranking of areas where clinical endpoints consultations and PPCs should be developed.

Action items and next steps

Meeting closed latest 1700